Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GB001

Other · developed by GB001, Inc, a wholly owned subsidiary of Gossamer Bio

Phase 2 Most advanced trial (none active)
GOSS Developer
1 Registered trials

What is GB001?

GB001 is an investigational drug studied in Asthma.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. (GOSS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03683576 Phase 2 Asthma Completed GOSS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Asthma

More from GB001, Inc, a wholly owned subsidiary of Gossamer Bio

GB004 Phase 1 GB1275 Phase 1 GB5121 Phase 1 Seralutinib Phase 3

Follow GOSS, the company behind GB001

See GOSS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GOSS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.